Malaria
Conditions
Interventions
R21 Matrix M boosters delivered via routine EPI clinics
R21 Matrix M boosters delivered via community based mass vaccination campaigns
Sponsors
University Of Sciences Techniques And Technologies De Bamako USTTB
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Residence of the study child’s family in the trial area with an intention to stay in the trial area for the duration of the trial. Age 0-5 months. Provision of informed consent for their child to join the trial from the parents or guardians.
Exclusion criteria
Exclusion criteria: Prior receipt of a malaria vaccine or other experimental malaria intervention such as a monoclonal antibody. Illness which in the opinion of the investigators would not warrant inclusion of a child in a clinical trial, for example severe malnutrition.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Coverage with the first and second booster doses of the R21/Matrix-M vaccine. ;The incidence of clinical malaria, detected through passive case detection at a clinic or hospital and diagnosed by RDT or a blood smear, during the period from 5 to 36 months of age. | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospital admissions due to malaria and all other causes excluding injuries and elective surgery during the period from 5 to 36 months of age;Death due to malaria and all other cause excluding injuries and elective surgery during the period from 5 to 36 months of age;Coverage of SMC, ITN use and other EPI vaccines;Prevalence of malaria parasite and anaemia at the end of the transmission season in year 2 (post-booster 1) and year 3 (post booster 2) of the trial | — |
Countries
Mali
Contacts
Public ContactLuca Meesters
Project Manager
Outcome results
None listed